Brief: Dianthus Therapeutics Announces Positive Data For Claseprubart From The Phase 2 Magic Trial In Generalized Myasthenia Gravis
08/09/2025 12:32
Sept 8 (Reuters) - Dianthus Therapeutics Inc DNTH.O: DIANTHUS THERAPEUTICS ANNOUNCES POSITIVE DATA FOR CLASEPRUBART (DNTH103) FROM THE PHASE 2 MAGIC TRIAL IN GENERALIZED MYASTHENIA GRAVIS, SUPPORTING ITS POTENTIAL BEST-IN-CLASS PROFILE DIANTHUS THERAPEUTICS INC - CLASEPRUBART SHOWS FAVORABLE SAFETY PROFILE DIANTHUS THERAPEUTICS INC - PHASE 3 GMG TRIAL FOR CLASEPRUBART ANTICIPATED TO START IN 2026 Source text: ID:nGNX26yXrC Further company coverage: DNTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dianthus Therapeutics
See all newsU.S. RESEARCH ROUNDUP- Adobe, Chewy, Mosaic
Brief: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Dianthus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dianthus Therapeutics Q2 net loss widens as R&D costs rise